NCT06914635Recruiting
Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)
Source: ClinicalTrials.gov · Last updated 6 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The project comprises two research lines. In the line 1, human monoclonal antibodies toward SARS-CoV-2 will be generate and characterized by in vitro functional tests. In the line 2, in vitro tests will be performed to evaluate the efficency of immune response mediated by antibodies direct to specific tumor molecules.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 21 Mar 2025
- Start date
- 30 May 2023
- Primary completion date
- 19 Feb 2025
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06914635
What you commit to
- Study type: Observational
- Planned participants: 40
- From 30 May 2023 to the primary completion date, 19 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active autoimmune disease ongoing treatment with immunosuppressive therapy
- Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months
- Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies
- Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \>3 years prior to signing informed consent and considered low risk of relapse
Other illness
- Line 1: - Active or history of neoplastic malignancy
- Evidence of positive HIV, HCV, HBV test
- Diabetes
- Chronic autoimmune or inflammatory diseases
- HIV infection
- Failure to sign informed consent form
Who the study is looking for
- Line 1: - Age \>18 at time of signing informed consent form
- Signed informed consent form Line 2: - Primery liver tumor
- Age \>18 at time of signing informed consent form
- Signed informed consent form
Age in the registry: 18 years to 90 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS Policlinico San Matteo di Pavia Coordinator of this site? Confirm its status | Pavia | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.